Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist[1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia.

It was also being studied for the treatment of ascites.

[2] Development was discontinued in 2009.

[3] This drug article relating to the cardiovascular system is a stub.

You can help Wikipedia by expanding it.